Protein Kinase C delta (PKCδ) Inhibitors
Activated PKCδ inhibits RAS degradation which in turn stimulates tumor growth.
Early-Stage Preclinical Program
- 30% of all human malignancies display activating RAS mutations with another 60% showing over-activity of Ras-signaling pathways.
- BriaCell’s novel, proprietary PKCδ inhibitors have shown activity against multiple RAS transformed tumors.
- This target has an attractive safety profile based on in vivo studies and knock out mouse studies.
- PKCδ also has potential activity as an immunotherapeutic by blocking TGFβ signaling.
- PKCδ inhibitors are applicable to specific niche tumor types which provide an accelerated clinical development plan.
- Could be in clinic within 24 months
- Provides Cost-Effective Additional Shot-on-Goal and additional partnership opportunities.
- Structural aspects of first generation inhibitor rottlerin and staurosporine(pan-PKC activator) were combined to create second generation inhibitor KAM1
- Third generation inhibitors such as BJE6-106 have improved potency and selectivity.
- Fourth generation inhibitors under development to optimize drug-like characteristics.
- PKCδinhibitors lack endothelial cell cytotoxicity & PKCδdeficient mice develop normally and are fertile → No marked intrinsic toxicity by inhibiting PKCδ
PKCδInhibitors Block Growth in Various Cancers
PKCδ inhibitor reduces tumor burden in a human lung cancer model (lower is better)
PKCδ inhibitors block growth of melanoma cells (lower is better)
PKCδ inhibitors inhibit growth of neuroendocrine tumor cell lines (lower is better)
PKC δinhibitors decrease tumor size and improve survival in pancreatic cancer model
(A) lower is better
(B) higher is better